Evidence map›Paper›PMID 31658717›Full record

ArticleMetabolites2019

Oxygraphy Versus Enzymology for the Biochemical Diagnosis of Primary Mitochondrial Disease.

Matthew J Bird, Isabelle Adant, Petra Windmolders, Ingrid Vander Elst, Catarina Felgueira, Ruqaiah Altassan, Sarah C Gruenert, Bart Ghesquière, Peter Witters, David Cassiman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Matthew J BirdLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, 3000 Leuven, Belgium. matthew.bird@kuleuven.be.
Isabelle AdantLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, 3000 Leuven, Belgium. isabelle.adant@kuleuven.be.
Petra WindmoldersLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, 3000 Leuven, Belgium. petra.windmolders@kuleuven.be.
Ingrid Vander ElstLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, 3000 Leuven, Belgium. ingrid.vanderelst@kuleuven.be.
Catarina FelgueiraLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, 3000 Leuven, Belgium. catarina.amf@gmail.com.
Ruqaiah AltassanMedical Genetics Department, King Faisal Specialist Hospital and Research Center, KSA MCD, Riyadh 43228, Saudi Arabia. altassanr@gmail.com.
Sarah C GruenertDepartment of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center-University of Freiburg, Faculty of Medicine, 79106 Freiburg, Germany. sarah.gruenert@uniklinik-freiburg.de.
Bart GhesquièreMetabolomics Expertise Center, Center for Cancer Biology, CCB-VIB, 3000 Leuven, Belgium. bart.ghesquiere@kuleuven.vib.be.
Peter WittersMetabolic Center, University Hospitals Leuven, 3000, Leuven, Belgium. peter.witters@uzleuven.be.ORCID 0000-0002-9264-6153
David CassimanLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, 3000 Leuven, Belgium. david.cassiman@kuleuven.be.
Pieter VermeerschClinical Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium. pieter.vermeersch@kuleuven.be.ORCID 0000-0001-7076-061X
KU Leuven · BEVIB-KU Leuven Center for Cancer Biology · BEKing Faisal Specialist Hospital & Research Centre · SAUniversity of Freiburg · DE

Funding

Fonds Wetenschappelijk Onderzoek T001116NKU Leuven EFF-D2860-C14/17/110
6 · The paper itself

Abstract

Primary mitochondrial disease (PMD) is a large group of genetic disorders directly affecting mitochondrial function. Although next generation sequencing technologies have revolutionized the diagnosis of these disorders, biochemical tests remain essential and functional confirmation of the critical genetic diagnosis. While enzymological testing of the mitochondrial oxidative phosphorylation (OXPHOS) complexes remains the gold standard, oxygraphy could offer several advantages. To this end, we compared the diagnostic performance of both techniques in a cohort of 34 genetically defined PMD patient fibroblast cell lines. We observed that oxygraphy slightly outperformed enzymology for sensitivity (79 ± 17% versus 68 ± 15%, mean and 95% CI), and had a better discriminatory power, identifying 58 ± 17% versus 35 ± 17% as "very likely" for oxygraphy and enzymology, respectively. The techniques did, however, offer synergistic diagnostic prediction, as the sensitivity rose to 88 ± 11% when considered together. Similarly, the techniques offered varying defect specific information, such as the ability of enzymology to identify isolated OXPHOS deficiencies, while oxygraphy pinpointed PDHC mutations and captured POLG mutations that were otherwise missed by enzymology. In summary, oxygraphy provides useful information for the diagnosis of PMD, and should be considered in conjunction with enzymology for the diagnosis of PMD.

Indexed as

diagnosticsenzymologyoxidative phosphorylation (OXPHOS)oxygraphyPrimary mitochondrial disease (PMD)respiration

Identifiers

PMID31658717
PMCPMC6835216
OpenAlexW2980294595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.